IDNA iShares Genomics Immnlgy & Hlthcr ETF
NYSE FactSet Glb Gnmcs&Imm Bio NR USD

NAV as of 13-May-2022

28.6758

4 Week: 26.66 - 32.81

52 Week: 26.66 - 55.47

Latest Closing Price

28.62

Premium / Discount

-0.19

Expense Ratio

0.47%

Investment Objective

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.

Main Fund Characteristics

Fund Manager:
iShares
Asset Under Management:
180,094,554
Launch Date:
10/06/2019
Asset Class:
Equity
Replication Method:
Physical-Sample
Number of Holdings:
61
Trading Currency:
USD
Style:
Mid Blend
Region/Sector/Strategy:
N.A / Healthcare / N.A
Exchange:
NYSE

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-34.672.50-13.88
1 Day4.450.000.00
1 Week-1.4111.23-0.13
1 Month-17.0413.53-1.26
3 Months-18.2520.41-0.89
6 Months-40.4626.19-1.54
1 Year-34.4031.56-1.09
2 Years-17.7744.97-0.40
3 Years0.000.000.00
5 Years0.000.000.00
10 Years0.000.000.00

Price History

-

Annual Performance Return

2012201320142015201620172018201920202021
Price (%) 0.00000.00000.00000.00000.00000.00000.00000.000054.4943-4.0033
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.00000.00000.00000.00000.00007.000082.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
N.A

Portfolio Data

Total Number of Holdings: 61

Number of Bond Holdings: 0

Number of Equity Holdings: 51

Total Market Value: 180,094,554

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Exelixis Inc7.5829689,1912,09613,645,982
2Ono Pharmaceutical Co Ltd7.1886498,9001,10012,936,392
3Sanofi SA6.8110120,78252412,256,985
4Takeda Pharmaceutical Co Ltd6.5747419,200011,831,770
5Regeneron Pharmaceuticals Inc6.322417,947011,377,680

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant18.55
Large31.82
Medium12.93
Small22.61
Micro13.59

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

12.6503

Price/Book*

2.0064

Price/Sales*

1.0748

Price/Cash Flow*

9.3370

Dividend Yield*

1.1599

Growth Measures

Long-Term Earnings

17.2211

Historical Earnings

28.3057

Sales Growth

11.1741

Cash-Flow Growth

26.6625

Book-Value Growth

14.4253

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.